Barclays Upgrades Relay Therapeutics to Overweight, Maintains Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson upgraded Relay Therapeutics (NASDAQ:RLAY) from Equal-Weight to Overweight while maintaining the price target at $15.
May 10, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Relay Therapeutics was upgraded by Barclays from Equal-Weight to Overweight, with the price target held steady at $15, indicating a positive outlook on the stock.
Upgrades by major financial institutions like Barclays often lead to increased investor confidence and can result in a short-term price increase. The maintenance of the price target at $15 suggests that Barclays believes the stock is currently undervalued or has strong growth potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100